Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: A comprehensive review of reported cases: Review article

Transplant Infectious Disease

Volumn 11, Issue 5, 2009, Pages 383-392

  Styczynski, J ^a   Einsele, H ^b   Gil, L ^c   Ljungman, P ^d  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Epstein Barr virus; Hematopoietic stem cell transplantation; Post transplant lymphoproliferative disorder; Treatment

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CD20 ANTIBODY; CIDOFOVIR; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; NUCLEOSIDE ANALOG; RITUXIMAB; THYMOCYTE ANTIBODY; VINCRISTINE; VIRUS DNA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DNA DETERMINATION; DRUG DOSE REDUCTION; DRUG EFFICACY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS RELATED POST TRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE TRANSFUSION; LYMPHOPROLIFERATIVE DISEASE; MORTALITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECIPIENT; REVIEW; RISK REDUCTION; SURVIVAL RATE; THERAPY EFFECT; VIRUS CARCINOGENESIS; VIRUS INFECTION; VIRUS LOAD; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOPROLIFERATIVE DISORDERS; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 70349658396     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2009.00411.x     Document Type: Review

References (110)

1. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999 94 : 2208 2216.
2. Gong JZ, Bayerl MG, Sandhaus LM, et al. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children. Am J Surg Pathol 2006 30 : 328 336.
3. Barker JN, Martin PL, Coad JE, et al. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant 2001 7 : 395 399.
4. Lange A, Klimczak A, Dlubek D, Dybko J. B-cell lymphoproliferative syndrome and peripheral blood CD20+ cells expansion after hematopoietic stem cell transplantation: association with fludarabine and anti-thymocyte globulin containing conditioning regimen. Transplant Proc 2003 35 : 3093 3095.
5. Takahashi S, Watanabe D, Miura K, et al. Epstein-Barr virus-associated post-transplant lymphoproliferative disorder presenting with skin involvement after CD34-selected autologous peripheral blood stem cell transplantation. Eur J Dermatol 2007 17 : 242 244.
6. Balamuth NJ, Nichols KE, Paessler M, Teachey DT. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 2007 29 : 569 573.
7. Nozzoli C, Bartolozzi B, Guidi S, et al. Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2006 47 : 167 169.
8. Rudzki Z, Werda L, Piatkowska-Jakubas B, et al. Fatal post-transplant lymphoproliferative disorder following allogeneic bone marrow transplantation for aplastic anemia. Pol J Pathol 2002 53 : 35 40.
9. McGuirk JP, Seropian S, Howe G, Smith B, Stoddart L, Cooper DL. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplant 1999 24 : 1253 1258.
10. Teira P, Agbalika F, Bergeron A, et al. Primary Epstein-Barr virus infection with pneumonia transmitted by allogeneic bone marrow after transplantation. Clin Infect Dis 2006 43 : 892 895.
11. Cohen JM, Sebire NJ, Harvey J, et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/ immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation. Blood 2007 110 : 2209 2214.
12. Trahair TN, Wainstein B, Manton N, et al. Rituximab for lymphoproliferative disease prior to haematopoietic stem cell transplantation for X-linked severe combined immunodeficiency. Pediatr Blood Cancer 2008 50 : 366 369.
13. Hanel M, Fiedler F, Thorns C. Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie 2001 24 : 491 494.
14. Kunitomi A, Arima N, Ishikawa T. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders presented as interstitial pneumonia; successful recovery with rituximab. Haematologica 2007 92 : e49 e52.
15. Comoli P, Basso S, Zecca M, et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007 7 : 1648 1655.
16. Zhu KE, Li JP, Zhang T, Zhong J, Chen J. Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation. Hematology 2007 12 : 117 121.
17. Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006 108 : 2874 2880.
18. Hubacek P, Cinek O, Kulich M, et al EBV quantification in children after allogeneic hematopoietic stem cell transplantation Cas Lek Cesk 2006 145 : 301 306.
19. Stuhler G, Knop S, Topp MS, et al. Intravenously administered rituximab induces remission of EBV associated non Hodgkin lymphoma confined to the brain in a patient after allogeneic stem cell transplantation. Haematologica 2006 91 : ECR01.
20. Kasow KA, Leung W, Horwitz EM, Woodard P, Handgretinger R, Hale GA. EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation. Pediatr Blood Cancer 2007 49 : 869 872.
21. Zhu K, Chen J, Chen S. Treatment of Epstein-Barr virus-associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review. Hematology 2005 10 : 365 370.
22. Greenfield HM, Gharib MI, Turner AJ, et al. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patient: can it successfully predict outcome and guide intervention? Pediatr Blood Cancer 2006 47 : 200 205.
23. Carpenter PA, Lowder J, Johnston L, et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2005 11 : 465 471.
24. Shimasaki N, Mori T, Shimada H, et al. Epstein-Barr virus-associated posttransplant lymphoproliferative disorder after a cord blood stem cell transplantation presenting with pulmonary nodules. J Pediatr Hematol Oncol 2004 26 : 124 127.
25. Shoji N, Ohyashiki JH, Suzuki A, et al. Multiple pulmonary nodules caused by B-cell post-transplant lymphoproliferative disorder after bone marrow transplantation: monitoring Epstein-Barr virus viral load. Jpn J Clin Oncol 2003 33 : 408 412.
26. Gruhn B, Meerbach A, Hafer R, Zell R, Wutzler P, Zintl F. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003 31 : 1023 1025.
27. Park S, Noguera ME, Briere J, et al. Successful rituximab treatment of an EBV-related lymphoproliferative disease arising after autologous transplantation for angioimmunoblastic T-cell lymphoma. Hematol J 2002 3 : 317 320.
28. Tinchon C, Auner HW, Beham-Schmid C, Aberle SW, Sill H, Linkesch W. Symptomatic Epstein-Barr virus reactivation in a patient with acute myeloid leukaemia and treatment with the monoclonal anti-CD20 antibody rituximab. Eur J Haematol 2002 69 : 50 53.
29. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002 99 : 4364 4369.
30. Carpenter PA, Appelbaum FR, Corey L, et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002 99 : 2712 2719.
31. Skoda-Smith S, Douglas VK, Mehta P, Graham-Pole J, Wingard JR. Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab. Bone Marrow Transplant 2001 27 : 329 332.
32. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000 11 (Suppl 1) : 113 116.
33. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000 95 : 1502 1505.
34. Annels NE, Kalpoe JS, Bredius RG, et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis 2006 42 : 1743 1748.
35. Orentas RJ, Schauer DW Jr., Ellis FW, Walczak J, Casper JT, Margolis DA. Monitoring and modulation of Epstein-Barr virus loads in pediatric transplant patients. Pediatr Transplant 2003 7 : 305 314.
36. Castagnola E, Dallorso S, Faraci M, et al. Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy. J Hematother Stem Cell Res 2003 12 : 9 10.
37. Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004 103 : 3979 3981.
38. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006 6 : 569 576.
39. Nishio M, Endo T, Fujimoto K, et al. Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. Eur J Haematol 2005 75 : 527 529.
40. Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis 2007 39 : 235 244.
41. Boesch RP, Daines M, Kaul A, Cotton R, Amin R. Lymphoproliferative disorder of the airway of an adolescent without immunodeficiency. Int J Pediatr Otorhinolaryngol 2005 69 : 1591 1594.
42. Imashuku S, Teramura T, Morimoto A, Naya M, Kuroda H. Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease. Bone Marrow Transplant 2004 33 : 129 130.
43. Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001 115 : 112 118.
44. Entz-Werle N, Cojean N, Barats A, et al. Lymphocyte data in Epstein-Barr-virus induced post-transplant lymphoproliferative disorder treated by rituximab. Pediatr Transplant 2003 7 : 277 281.
45. Sirvent-Von Bueltzingsloewen A, Sirvent N, Morand P, Cassuto JP. Fatal central nervous system lesions emerging during anti-CD20 monoclonal antibody therapy (Rituximab) for a post transplantation Epstein-Barr virus-linked lymphoma. Med Pediatr Oncol 2003 40 : 408 409.
46. Bernard F, Sarran N, Margueritte G, Barneon G, Astruc J. Successful treatment of an Epstein-Barr virus-associated B-cell lymphoproliferative disease in a child with acute lymphoblastic leukemia using an anti-CD20 monoclonal antibody. Med Pediatr Oncol 2001 36 : 329 331.
47. Stachel DK, Schmid I, Schuster F, Stehr M, Baumeister FA, Muller-Hocker J. Lymphoproliferative syndrome in an infant after stem cell transplantation: successful therapy with T-lymphocytes and anti-CD20 monoclonal antibodies. Med Pediatr Oncol 2000 35 : 503 505.
48. Faye A, Van Den Abeele T, Peuchmaur M, Mathieu-Boue A, Vilmer E. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet 1998 352 : 1285.
49. Ocheni S, Kroeger N, Zabelina T, et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008 42 : 181 186.
50. Clave E, Agbalika F, Bajzik V, et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004 77 : 76 84.
51. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998 92 : 1549 1555.
52. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996 2 : 551 555.
53. Liu Z, Savoldo B, Huls H, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res 2002 159 : 123 133.
54. Pakakasama S, Eames GM, Morriss MC, et al. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation 2004 78 : 755 757.
55. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003 3 : 801 812.
56. Hassan R, White LR, Stefanoff CG, et al. Epstein-Barr Virus (EBV) detection and typing by PCR: a contribution to diagnostic screening of EBV-positive Burkitt's lymphoma. Diagn Pathol 2006 1 : 17.
57. Crawford DH, Macsween KF, Higgins CD, et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis 2006 43 : 276 282.
58. Tierney RJ, Steven N, Young LS, Rickinson AB. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 1994 68 : 7374 7385.
59. Decker LL, Klaman LD, Thorley-Lawson DA. Detection of the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy individuals. J Virol 1996 70 : 3286 3289.
60. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000 343 : 481 492.
61. Heslop HE. Biology and treatment of Epstein-Barr virus-associated Non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program 2005 260 266.
62. Siu LL, Chan JK, Kwong YL. Natural killer cell malignancies: clinicopathologic and molecular features. Histol Histopathol 2002 17 : 539 554.
63. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991 337 : 320 322.
64. Anagnostopoulos I, Hummel M, Finn T, et al. Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 1992 80 : 1804 1812.
65. Purtilo DT. Epstein-Barr-virus-induced oncogenesis in immune-deficient individuals. Lancet 1980 1 : 300 303.
66. Miller G, Shope T, Coope D, et al. Lymphoma in cotton-top marmosets after inoculation with Epstein-Barr virus: tumor incidence, histologic spectrum antibody responses, demonstration of viral DNA, and characterization of viruses. J Exp Med 1977 145 : 948 967.
67. Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 2008 13 : 577 585.
68. Yousem SA, Randhawa P, Locker J, et al. Posttransplant lymphoproliferative disorders in heart-lung transplant recipients: primary presentation in the allograft. Hum Pathol 1989 20 : 361 369.
69. Newcombe DS. Immune surveillance, organophosphorus exposure, and lymphomagenesis. Lancet 1992 339 : 539 541.
70. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001 97 : 1165 1171.
71. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988 72 : 520 529.
72. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001 98 : 972 978.
73. Frey NV, Tsai DE. The management of posttransplant lymphoproliferative disorder. Med Oncol 2007 24 : 125 136.
74. Ho M. Risk factors and pathogenesis of posttransplant lymphoproliferative disorders. Transplant Proc 1995 27 : 38 40.
75. Sundin M, Le Blanc K, Ringden O, et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006 91 : 1059 1067.
76. Gartner BC, Schafer H, Marggraff K, et al. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol 2002 40 : 351 358.
77. Sullivan JL, Wallen WC, Johnson FL. Epstein-Barr virus infection following bone-marrow transplantation. Int J Cancer 1978 22 : 132 135.
78. Gratama JW, Lennette ET, Lonnqvist B, et al. Detection of multiple Epstein-Barr viral strains in allogeneic bone marrow transplant recipients. J Med Virol 1992 37 : 39 47.
79. Tashiro Y, Goto M, Takemoto Y, et al. Epstein-Barr virus-associated enteritis with multiple ulcers after stem cell transplantation: first histologically confirmed case. Pathol Int 2006 56 : 530 537.
80. Awaya N, Adachi A, Mori T, et al. Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma. Leuk Res 2006 30 : 1059 1062.
81. Simon M, Bartram CR, Friedrich W, et al. Fatal B-cell lymphoproliferative syndrome in allogeneic marrow graft recipients. A clinical, immunobiological and pathological study. Virchows Arch B Cell Pathol Incl Mol Pathol 1991 60 : 307 319.
82. Schwab M, Boswald M, Korn K, Ruder H. Epstein-Barr virus in pediatric patients after renal transplantation. Clin Nephrol 2000 53 : 132 139.
83. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009 113 : 1175 1183.
84. Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009 43 : 757 770.
85. Harris NL, Frizerra G, Knowles DM. Post-transplant lymphoproliferative disorders. In : Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. Lyon : IARC Press, 2001 : 264 269.
86. Nalesnik MA. The diverse pathology of post-transplant lymphoproliferative disorders: the importance of a standardized approach. Transpl Infect Dis 2001 3 : 88 96.
87. Capello D, Berra E, Cerri M, Gaidano G. Post-transplant lymphoproliferative disorders. Molecular analysis of histogenesis and pathogenesis. Minerva Med 2004 95 : 53 64.
88. Kutok JL, Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 2006 1 : 375 404.
89. Burney K, Bradley M, Buckley A, Lyburn I, Rye A, Hopkins R. Posttransplant lymphoproliferative disorder: a pictorial review. Australas Radiol 2006 50 : 412 418.
90. Muti G, Cantoni S, Oreste P, et al. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 2002 87 : 67 77.
91. Muti G, Klersy C, Baldanti F, et al. Epstein-Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. Br J Haematol 2003 122 : 927 933.
92. Beck R, Westdorp I, Jahn G, Schafer H, Kanz L, Einsele H. Detection of Epstein-Barr virus DNA in plasma from patients with lymphoproliferative disease after allogeneic bone marrow or peripheral blood stem cell transplantation. J Clin Microbiol 1999 37 : 3430 3431.
93. Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis 2001 3 : 79 87.
94. Aalto SM, Juvonen E, Tarkkanen J, et al. Lymphoproliferative disease after allogeneic stem cell transplantation - pre-emptive diagnosis by quantification of Epstein-Barr virus DNA in serum. J Clin Virol 2003 28 : 275 283.
95. Lankester AC, van Tol MJ, Vossen JM, Kroes AC, Claas E. Epstein-Barr virus (EBV)-DNA quantification in pediatric allogenic stem cell recipients: prediction of EBV-associated lymphoproliferative disease. Blood 2002 99 : 2630 2631.
96. Gartner BC, Fischinger J, Schafer H, Einsele H, Roemer K, Muller-Lantzsch N. Epstein-Barr viral load as a tool to diagnose and monitor post-transplant lymphoproliferative disease. Recent Results Cancer Res 2002 159 : 49 54.
97. Buyck HC, Ball S, Junagade P, Marsh J, Chakrabarti S. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia. Bone Marrow Transplant 2009 43 : 813 816.
98. Ghobrial IM, Otteman LA, White WL. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. N Engl J Med 2003 349 : 2570 2572.
99. Cohen J, Gandhi M, Naik P, et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005 129 : 229 239.
100. Kluin-Nelemans HC, Coenen JL, Boers JE, van Imhoff GW, Rosati S. EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood 2008 112 : 1039 1041.
101. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000 96 : 4055 4063.
102. Meijer E, Cornelissen JJ. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol 2008 15 : 576 585.
103. Gandhi MK, Wilkie GM, Dua U, et al. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant 2007 7 : 1293 1299.
104. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995 345 : 9 13.
105. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000 95 : 807 814.
106. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005 56 : 155 167.
107. Everly MJ, Bloom RD, Tsai DE, Trofe J. Posttransplant lymphoproliferative disorder. Ann Pharmacother 2007 41 : 1850 1858.
108. Cesaro S, Murrone A, Mengoli C, et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005 128 : 224 233.
109. Davis CL, Harrison KL, McVicar JP, et al. Antiviral prophylaxis and the Epstein-Barr virus-related post-transplant lymphoproliferative disorder. Clin Transplant 1995 9 : 53 59.
110. Oertel SH, Riess H. Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations. Recent Results Cancer Res 2002 159 : 89 95.